Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Howard I. Scher, Andrew J. Armstrong, Susan F. Slovin et al.|Journal of Clinical Oncology|2016Cited by 1.6k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Johann S. de Bono, Christopher M. Haqq et al.|The Lancet Oncology|2012Cited by 1.4k
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerMatti Annala, Kim N., Gillian Vandekerkhove et al.|Cancer Discovery|2018Cited by 520
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerAlexander W. Wyatt, Kim N., Arun Azad et al.|JAMA Oncology|2016Cited by 384
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerKim N., Celio Kussumoto, Dana E. Rathkopf et al.|Journal of Clinical Oncology|2023Cited by 317